Trial Profile
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of SHR4640 in Male Subjects With High Serum Uric Acid Level
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Ruzinurad (Primary)
- Indications Gout; Hyperuricaemia
- Focus Adverse reactions
- Sponsors Atridia
- 20 Mar 2018 Status changed from recruiting to completed.
- 15 Oct 2017 Status changed from not yet recruiting to recruiting.
- 10 Jul 2017 New trial record